Fulcrum Therapeutics (FULC) EBIAT: 2020-2025
Historic EBIAT for Fulcrum Therapeutics (FULC) over the last 5 years, with Sep 2025 value amounting to -$19.6 million.
- Fulcrum Therapeutics' EBIAT rose 9.68% to -$19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.5 million, marking a year-over-year decrease of 321.56%. This contributed to the annual value of -$9.7 million for FY2024, which is 90.01% up from last year.
- Fulcrum Therapeutics' EBIAT amounted to -$19.6 million in Q3 2025, which was down 10.99% from -$17.7 million recorded in Q2 2025.
- In the past 5 years, Fulcrum Therapeutics' EBIAT ranged from a high of $55.4 million in Q2 2024 and a low of -$34.1 million during Q2 2022.
- In the last 3 years, Fulcrum Therapeutics' EBIAT had a median value of -$22.7 million in 2023 and averaged -$14.4 million.
- As far as peak fluctuations go, Fulcrum Therapeutics' EBIAT skyrocketed by 332.98% in 2024, and later crashed by 131.86% in 2025.
- Fulcrum Therapeutics' EBIAT (Quarterly) stood at -$23.5 million in 2021, then decreased by 11.29% to -$26.1 million in 2022, then increased by 5.28% to -$24.8 million in 2023, then skyrocketed by 33.07% to -$16.6 million in 2024, then increased by 9.68% to -$19.6 million in 2025.
- Its last three reported values are -$19.6 million in Q3 2025, -$17.7 million for Q2 2025, and -$16.6 million during Q4 2024.